A Regulator Looks Back On What We Learned From Accelerated SARS-CoV-2 Neutralizing mAbs Development

Prior knowledge, platforms, parallel backup programs, and strategic timing all come into play when rapidly scaling up a mAbs development program in...

Related Keywords

United States ,Salisbury ,Mashonaland East ,Zimbabwe ,Mexico ,Maria Teresa Gutierrez Lugo ,University Of Arizona ,Abs And Those In Development ,Public Health Emergency ,Health Services ,National Autonomous University Of Mexico ,Office Of Biotechnology Products ,Development Program ,Department Of Human ,Biotechnology Products ,Monoclonal Antibody Products ,Human Use ,That Leverage Experience From Licensed ,Industry And Regulators To Collaborate ,Products Targeting ,Including Addressing ,Emerging Variants ,Health Emergency ,Drug Substances ,Using Analytical Platform Technologies ,Support Accelerated Product Development ,Concept Review ,Pharmaceutical Science ,Teresa Gutierrez Lugo ,Emergency Use Authorization ,National Autonomous University ,